4 Analysts Have This to Say About ADC Therapeutics
Portfolio Pulse from Benzinga Insights
In the last quarter, 4 analysts have provided ratings for ADC Therapeutics (NYSE:ADCT), with 2 being bullish, 1 somewhat bullish, and 1 indifferent. The company has an average 12-month price target of $9.0, representing a 27.01% decrease from the previous average price target of $12.33.
July 25, 2023 | 3:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Analysts' ratings for ADC Therapeutics are mostly bullish, but the average 12-month price target has decreased by 27.01% to $9.0.
The majority of analysts are bullish on ADC Therapeutics, indicating a positive outlook. However, the decrease in the average 12-month price target suggests that they expect the stock price to decrease in the short term. This could lead to a neutral impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100